[18F]Fluoride PET-CT imaging for detection and monitoring of bone formation in spondyloarthritis - [18F]Fluoride PET in SpA

Vrije Universiteit Medisch Centrum0 个研究点目标入组 48 人开始时间: 待定最近更新: 2024年4月15日

试验速览

暂无简介。

•Diagnosis of psoriatic arthritis according to the 2006 Classification
•Criteria for Psoriatic Arthritis (CASPAR) or ankylosing spondylitis according
•to the ASAS criteria
•Patients with clinically active disease as assessed by a physician;
•o In PsA defined as clinically active disease with at least one clinically
•active enthesitis site and a clinical indication to start with Secukinumab
•o In AS defined as a Bath Ankylosing Spondylitis Disease Activity Index
•(BASDAI) of 4 or higher and a clinical indication to start with Secukinumab.
•Treatment with disease modifying anti-rheumatic drugs (DMARDS) and
•non-steroidal anti-inflammatory drugs (NSAID) is permitted, provided that there
•is a stable dose for at least 4 weeks prior to inclusion and during the study
•up to 12 weeks of follow up.
•Treatment with oral corticosteroids up to 10mg daily is permitted, provided
•that there is a stable dose for at least 4 weeks prior to inclusion and during
•the study up to 12 weeks of follow up.
•The anti-TNF control PsA group: prior treatment with one anti-TNF is
•permitted, given that the patient was intolerant for this anti-TNF (no primary
•The AS biopsy group: start with either biological or NSAID therapy is
•Patients must be able to adhere to the study appointments and other protocol
•requirements.
•Patients must be capable of giving informed consent and the consent must have
•been obtained prior to the study related procedures.

发起方